Abivax hires former Arena, Shire/Takeda exec as CCO

19 April 2023

French immunology company Abivax (Euronext Paris: ABVX) has appointed Michael Ferguson as its new chief commercial officer (CCO), effective immediately, and he will be based at the new Abivax subsidiary on the US East Coast.

As a result, Pierre Courteille, who held the CCO post, will be focusing on business development activities and is appointed chief business officer (CBO).

Abivax noted that it is strengthening its expertise in the commercial and business development field to foster the evolution of the company towards future commercialization of obefazimod, its first-in-class small molecule that has demonstrated safety and anti-inflammatory activity in ulcerative colitis (UC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK